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Background:  The c-Jun N-terminal kinases (JNKs) are members of the mitogen-
activated protein (MAP) kinase family, and regulate signal transduction in
response to environmental stress. Activation and nuclear localization of JNK3, a
neuronal-specific isoform of JNK, has been associated with hypoxic and ischemic
damage of CA1 neurons in the hippocampus. Knockout mice lacking JNK3
showed reduced apoptosis of hippocampal neurons and reduced seizure induced
by kainic acid, a glutamate-receptor agonist. Thus, JNK3 may be important in the
pathology of neurological disorders and is of significant medical interest.
Results:  We report here the structure of unphosphorylated JNK3 in complex
with adenylyl imidodiphosphate, an ATP analog. JNK3 has a typical kinase fold,
with the ATP-binding site situated within a cleft between the N- and C-terminal
domains. In contrast to other known MAP kinase structures, the ATP-binding
site of JNK3 is well ordered; the glycine-rich nucleotide-binding sequence forms
a β-strand–turn–β-strand structure over the nucleotide. Unphosphorylated JNK3
assumes an open conformation, in which the N- and C-terminal domains are
twisted apart relative to their positions in cAMP-dependent protein kinase. The
rotation leads to the misalignment of some of the catalytic residues. The
phosphorylation lip of JNK3 partially blocks the substrate-binding site.
Conclusions:  This is the first JNK structure to be determined, providing a
unique opportunity to compare structures from the three MAP kinase
subfamilies. The structure reveals atomic-level details of the shape of JNK3 and
the interactions between the kinase and the nucleotide. The misalignment of
catalytic residues and occlusion of the active site by the phosphorylation lip
may account for the low activity of unphosphorylated JNK3. The structure
provides a framework for understanding the substrate specificity of different
JNK isoforms, and should aid the design of selective JNK3 inhibitors.
Introduction
Mammalian cells respond to extracellular stimuli by acti-
vating members of the mitogen-activated protein (MAP)
kinase family, which include the extracellular signal regu-
lated kinases (ERKs), the p38 MAP kinases and the c-Jun
N-terminal kinases (JNKs). MAP kinases are serine/threo-
nine kinases that are activated by dual phosphorylation of
threonine and tyrosine residues of the Thr-X-Tyr
segment in a loop located adjacent to the active site [1,2].
Phosphorylation of each MAP kinase is carried out by spe-
cific kinases upstream of MAP kinase. Activated MAP
kinases then phosphorylate various substrates, including
transcription factors, which in turn regulate the expression
of specific sets of genes and thus mediate a specific
response to the stimulus. 
Members of the JNK family of kinases are activated by
proinflammatory cytokines tumor necrosis factor-α and
interleukin-1β as well as environmental stress, such as
anisomycin, UV irradiation, hypoxia and osmotic shock [2].
Three distinct genes encoding JNKs, Jnk1, Jnk2 and Jnk3,
have been identified and at least ten different splicing iso-
forms exist in mammalian cells [3]. The downstream sub-
strates of JNKs include the transcription factors c-Jun,
ATF-2, Elk1, NFAT, p53 and a cell death domain protein
[4–9]. Each JNK isoform binds to these substrates with dif-
ferent affinities, suggesting a regulation of signaling path-
ways by substrate specificity of different JNKs in vivo [3].
JNK1 and JNK2 are widely expressed in a variety of
tissues. In contrast, JNK3 is selectively expressed in the
brain and to a lesser extent in the heart and testis [3,10,11].
In the adult human brain, JNK3 expression is localized to a
subpopulation of pyramidal neurons in the CA1, CA4 and
subiculum regions of the hippocampus and layers 3 and 5
of the neocortex [10]. The CA1 neurons in brain biopsies
of patients diagnosed with acute hypoxia showed strong
nuclear JNK3 immunoreactivity. In contrast, control
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samples taken from patients with nonneuronal diseases
revealed only diffused cytoplasmic JNK3 staining in the
hippocampal neurons [9]. Furthermore, disruption of the
JNK3 gene caused resistance of mice to the excitotoxic
glutamate receptor agonist kainic acid, including the
effects on seizure activity, AP-1 transcriptional activity and
apoptosis of hippocampal neurons, indicating that the
JNK3 signaling pathway is a critical component in the
pathogenesis of glutamate neurotoxicity [12]. Thus, selec-
tive modulation of JNK3 activity could potentially provide
therapeutic intervention for neurodegenerative diseases
such as stroke and epilepsy.
To help understand the regulation of JNK3, and other
members of the JNK subfamily of protein kinases, we
have solved the crystal structure of unphosphorylated
JNK3α1 in complex with adenylyl imidodiphosphate
(AMP-PNP) and magnesium at 2.3 Å resolution. This is
the first JNK structure to be solved and, together with p38
and ERK2, provides a unique opportunity to compare
structures across the MAP kinase family.
Results and discussion
Crystallization of JNK3 in complex with MgAMP-PNP
Human JNK3α1 has an extended N terminus when com-
pared to JNK1, JNK2 and other MAP kinases (Figure 1)
[3]. For the purpose of crystallographic studies a truncated
form of JNK3, without the first 39 residues, was
expressed. Crystallization trials of this form of the enzyme
yielded small crystals that diffracted to 8 Å. Because
residues at the C terminus of ERK2 and p38 are disor-
dered [13,14], we reasoned that the C-terminal residues of
JNK3 might also be flexible and interfere with the forma-
tion of a well ordered crystal lattice. We therefore
searched for an active shortened form of JNK3 with C-ter-
minal truncation of the protein. JNK3 protein lacking the
N-terminal 39 and C-terminal 20 residues was found to
display similar kinase activity to the JNK3 protein without
the C-terminal truncation when activated by MAP kinase
kinase 7 (MKK7) [15] in vitro (see Materials and methods
section). This form of the protein could be used to grow
large, well-ordered crystals that diffract to at least 2.3 Å
resolution. The structure of JNK3 was solved using this
truncated enzyme (residues Ser40–Glu402).
Overall structure
The MAP kinase homologous region of JNK3 (residues
Phe48–Glu397) is 45% identical in amino acid sequence to
ERK2 and 51% identical to p38, the structures of which
have been reported [13,14] (Figure 1). As expected, the
overall architecture of JNK3 is highly similar to that of
ERK2 and p38. The N-terminal domain (residues 45–149
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Figure 1
Structure-based sequence alignment of JNK3,
p38, ERK2 and cAPK. The amino acid
sequences of human JNK3 [3], human p38
kinase [34], human ERK2 [35] and murine
cAPK [36] are aligned based on structural
similarity. The divergent N- and C-terminal
regions of p38, ERK2 and cAPK are not
shown. The N- and C-terminal residues that
were not included in the truncated JNK3
(residues Ser40–Glu402) used for
crystallographic studies are denoted by
lowercase letters. Residues omitted from the
model are italicized. The subdomains are
labeled by Roman numerals according to
reference [37]. The secondary structure
elements for JNK3 are indicated above the
sequences (nomenclature as for Figure 2a),
with open boxes designating α and 310
helices and open arrows designating β
strands. Disordered regions are indicated with
dashed lines. Both the JNK3 and cAPK
sequence numbering are shown, above and
below the alignment, respectively.
Phosphorylation sites in the phosphorylation
lip are denoted by an asterisk. JNK3 residues
that differ from JNK1 and JNK2 [3,38,39] are
highlighted in bold.
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Structure
and 379–400) of JNK3 contains mostly β strands, whereas
the C-terminal domain (residues 150–211 and 217–374) is
predominantly α helical. A deep cleft between the two
domains comprises the ATP-binding site, where the
glycine-rich sequence (Gly71-Ser-Gly-Ala-Gln-Gly-Ile-
Val78) of JNK3 forms a well-defined β-strand–turn–β-
strand structure over the nucleotide. The insertion in the
C-terminal domain that is characteristic for MAP kinases
is 12 residues longer in JNK3 (residues 283–328) than in
ERK2 and p38, resulting in the N-terminal extension of
helix αH and an extra 310 helix (Figure 2a). We refer to
this 12-residue insertion as ‘the JNK insertion’ as it is
present in all c-Jun N-terminal kinases [3].
The relative orientation of the N- and C-terminal domains
is different among the structures of JNK3, ERK2 and p38
(Figure 2b). A superposition of the C-terminal domains of
ERK2 and p38 onto the C-terminal domain of JNK3
revealed rotations of the N-terminal domains of ERK2
and p38 by about 2.5° and 4°, respectively. Despite this
rotation, the structures of the individual domains of JNK3,
ERK2 and p38 are similar. Independent superposition of
the N- and C-terminal domains of ERK2 onto JNK3,
excluding the phosphorylation lip region, the glycine-rich
sequence, the JNK insertion and the protein termini,
yielded protein backbone root mean square (rms) devia-
tions of 1.15 Å for the N-terminal domain (residues
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Figure 2
The overall fold of JNK3 and comparison to ERK2. (a) Ribbon
representation of the overall fold of JNK3 complexed with MgAMP-
PNP. Blue indicates secondary structure elements and loops that are
conserved among protein kinases; magenta indicates extensions and
insertions characteristic for MAP kinases. The JNK insertion (residues
Leu317–Lys328) and the phosphorylation lip (residues
Ser217–Thr226) are colored in cyan and red, respectively. The bound
AMP-PNP (yellow) and two Mg2+ ions (orange) are shown in ball-and-
stick representation. The Cα positions of the regulatory
phosphorylation sites, Thr221 and Tyr223, are shown and labeled.
Secondary structure elements are labeled according to [13]. Electron
density is not visible for two disordered regions within the core of
JNK3 as shown by the dotted lines. One of these disordered regions is
Arg212–Thr216 in the C-terminal domain (the corresponding residues
in ERK2 form β strand β9 that precedes the phosphorylation lip). The
second disordered region includes residues Gln374–Lys378. The
structure of phosphorylated ERK2 showed that this portion of L16 is
rearranged into a 310 helix upon phosphorylation [19]. (This diagram
was constructed using the program RIBBONS [40].) (b) Stereoview
superposition of JNK3–MgAMP-PNP and ERK2 (entry code 1ERK in
the Protein Data Bank [13]). Cα representations of the structures of
JNK3 (yellow and red) and ERK2 (blue and white) are shown after
superposition of their C-terminal domains. Segments with the largest
structural divergence are the glycine-rich loop (residues Gly71–Val78
in JNK3) and the phosphorylation lip (labeled lip; residues
Ser217–Thr226 in JNK3), which are highlighted as thick bonds.
Superposition of the C-terminal domain of ERK2 onto JNK3 reveals a
2.5 Å shift in the Cα position of Thr226 relative to Thr188 in ERK2.
The conformation of Thr226 is also different when compared to
Thr188 in ERK2. In JNK3, a pair of water molecules are hydrogen
bonded to the mainchain carbonyl and amide groups of Thr226, and
mediate interactions with the sidechain of Lys199. As a result, Thr226
adopts different φ, ψ angles (Thr226 of JNK3, φ = –88° and ψ = 114°;
Thr188 of ERK2, φ = –46° and ψ = 130°), which redirects the path of
the phosphorylation lip. Most of the JNK3 residues in the
phosphorylation lip (residues Ser217–Thr226) are well ordered, with B
factors of the sidechains of Phe209, Leu210, Phe218 and Met220
refined to below 25 Å2. In addition, the N-terminal portion of the lip
(Ser217–Met220) makes contacts with the N-terminal portion of the
αC helix, which in turn contacts the glycine-rich flap covering the
nucleotide; the C-terminal portion of the lip (Val225 and Thr226)
interacts with part of L9. The residues Thr221–Val224 are solvent
exposed. Another significant difference between JNK3 and ERK2 is
the position of the glycine-rich loop: the loop in JNK3 is moved
towards the triphosphate chain of AMP-PNP, whereas it is partially
disordered in ERK2. The glycine-rich loop has conformational
flexibility — its rigid conformation is promoted by nucleotide binding. 
56–149 and 382–400 in JNK3) and 1.58 Å for the C-termi-
nal domain (residues 150–208, 226–315 and 329–369 in
JNK3). A similar comparison of JNK3 and p38 showed
protein backbone rms deviations of 1.23 Å for the N-ter-
minal domain and 1.60 Å for the C-terminal domain.
The phosphorylation lip
The region spanning residues Ser217–Thr226 contains the
JNK3 regulatory phosphorylation sites, Thr221 and
Tyr223, and is referred to as the ‘phosphorylation lip’ or
‘activation loop’ (Figure 2a). The residue between the two
phosphorylation sites in the Thr-X-Tyr tripeptide
sequence of JNK3 is proline, whereas this residue is gluta-
mate in ERK2 and glycine in p38. The phosphorylation
lip is four residues shorter in JNK3 than in ERK2, and two
residues longer than in p38. These differences result in
the changes in the position and conformation of the activa-
tion residues, and in the path of the phosphorylation lip in
the three kinases.
The phosphorylation residues in JNK3 have a different
position and conformation when compared to the corre-
sponding amino acids in ERK2 and p38. Thr221 and
Tyr223 are 16 Å and 12 Å away from the location of the
corresponding residues in ERK2 and p38, respectively.
Despite the different locations, the regulatory threonine
residues in all three enzymes are solvent exposed. The
local environments of the tyrosine residues are different,
however. The sidechain of Tyr223 in JNK3 is exposed
to solvent and is disordered. The corresponding tyrosine
residue in p38 is also solvent accessible, but is well
ordered and interacts with the hydroxyl group of Thr221
through a water molecule [14]. In contrast, the sidechain
of Tyr185 in unphosphorylated ERK2 is buried, forms a
hydrogen bond with the sidechain of Arg146, and makes
van der Waals contacts with nearby hydrophobic amino
acid residues [13]. The conformation of Tyr185 in the
unphosphorylated ERK2 structure suggests that the
phosphorylation lip must be refolded before Tyr185 can
become a substrate for the ERK2 upstream activating
kinases. A similar movement may not be needed to
phosphorylate Thr221 and Tyr223 in JNK3, as these
residues are already accessible to solvent in the unphos-
phorylated form.
The peptide substrate binding channel
The structure of the ternary complex formed between
cAMP-dependent protein kinase (cAPK), the inhibitor
peptide PKI(5–24) and MnAMP-PNP, is believed to rep-
resent the bioactive conformation for protein kinases
[16–18]. The cAPK complex shows that the peptide-
binding channel lies mainly in the C-terminal domain, and
that the P+1 binding site is formed by a loop (residues
Leu198–Leu205 in cAPK) contiguous with the phos-
phorylation lip and connecting to αL12 (Figure 3). The
C-terminal domain of JNK3 superimposes well with that
of cAPK. Thus the residues that are likely to be important
for JNK3 peptide substrate binding may be mapped by its
homology to cAPK (Figure 1).
The protein backbone of residues Arg227–Arg230 in
JNK3 has a conformation similar to the corresponding
residues in cAPK (residues Pro202–Leu205), but the
sidechain of Arg230 fills the P+1 site in an unfavorable
conformation for binding substrate (Figure 3). In addition,
some of the residues in the JNK3 phosphorylation lip
(residues Tyr223–Thr226 in JNK3 corresponding to
residues Leu198–Thr201 in cAPK) take a path distinct
from that of cAPK and occupy the positions of P–1 to P+2
sites of the peptide substrate (Figure 3).
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Figure 3
Stereoview superposition of JNK3 and cAPK
(entry code 1APK in the Protein Data Bank
[16]). Cα representations of JNK3 (yellow)
and the cAPK ternary complex (blue and red)
are shown after superposition of their 
C-terminal domains. The phosphorylation lip in
JNK3 and cAPK together with the PKI
inhibitor (red) are shown as thick bonds. The
figure illustrates the difference in the
conformation of the lip between the two
enzymes, and shows the lip of JNK3
occupying part of the peptide-binding
channel. In the cAPK ternary complex,
MnAMP-PNP is omitted from the drawing and
only the kinase catalytic core portion (residues
Asp41–Trp296) of cAPK is shown. P refers to
the putative phosphorylation residue of a
peptide substrate.
Phosphorylation-related conformational changes in the
phosphorylation lip as well as the peptide substrate binding
channel have been observed in the crystal structures of
unphosphorylated and phosphorylated ERK2 [13,19].
Comparison of the JNK3 structure with the structure of
phosphorylated ERK2 suggests how phosphorylation at
Thr221 and Tyr223 might play a role in the activation of
JNK kinases. In the structure of phosphorylated ERK2,
phosphothreonine 183 interacts with three arginine
residues — Arg68 in αC, Arg146 in the catalytic loop (C
loop) and Arg170 from the phosphorylation lip — whereas
phosphotyrosine 185 is ligated by Arg189 and Arg192 [19].
If Thr221 and Tyr223 are ligated similarly in the phospho-
rylated form of JNK3, they would have to move by approxi-
mately 15 Å, and a large conformational change of the
phosphorylation lip would be required. As a consequence,
the restructuring of the phosphorylation lip could help to
unblock the peptide substrate binding channel.
The active site
Crystallization of JNK3 with AMP-PNP and Mg2+ has
yielded structural data for the nucleotide-bound form of
JNK3. AMP-PNP is bound in a deep cleft between the
two domains of JNK3 (Figure 2a). The binding of the
nucleotide analog is similar to that found in the ternary
complex formed by cAPK, MnAMP-PNP and the
inhibitor peptide PKI(5–24) [16] (Figure 4a). These find-
ings differ from previous crystal soaking experiments with
ERK2 [13], and permit a more detailed description of the
interactions between JNK3 and the nucleotide.
Protein kinases contain a nucleotide binding sequence
Gly-X-Gly-X-X-Gly-X-X that is referred to as ‘the glycine-
rich phosphate anchor loop’ due to its sequence and role in
nucleotide binding [20]. The glycine-rich loop is well
defined in JNK3 and superimposes well with that of cAPK,
with an rms deviation of 0.54 Å for the protein mainchain
atoms from Ile70 to Ser79. The glycine-rich sequence in
JNK3 (Gly71-Ser–Gly-Ala-Gln-Gly-Ile-Val78) forms a flap
over the nucleotide, covering it almost completely. In con-
trast, the glycine-rich loops of the apo forms of ERK2 and
p38 are partially disordered.
The adenine base of the nucleotide is bound in the back of
the domain interface. The amino group (N6) forms a
hydrogen bond to the backbone carbonyl of Glu147, and
N1 accepts a proton from the backbone amide of Met149.
Nonpolar interactions are found at both sides of the purine
ring, including Ile70 and Val78 from the glycine-rich flap
on one side, and Val196 from β7 on the other. The ribose
O2′ and O3′ hydroxyls form a hydrogen-bonding network
to the sidechain of Asn152 and the carbonyl group of
Ser193. The triphosphate group forms many hydrogen
bonds involving directly, or indirectly, most of the invariant
amino acids of protein kinases. Hydrogen bonds to the
phosphate oxygen atoms are formed by the mainchain
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Figure 4
The active site of JNK3. (a) Stereoview of the
active site of JNK3. A molecule of AMP-PNP
and two Mg2+ ions are shown together with
their surrounding JNK3 residues. The AMP-
PNP molecule is shown as thick bonds and
the protein residues as thin bonds. Two Mg2+
ions (colored orange and labeled M1 and M2)
and two water molecules (colored cyan and
labeled W1 and W2) are shown as spheres.
Hydrogen bonds are indicated by dashed
lines. (b) Detailed comparison of the active
site of JNK3 with that of cAPK. The figure
shows Cα representations of the ATP-binding
sites of JNK3 (yellow) and cAPK (blue) with
the sidechains of selected residues included.
The atoms of AMP-PNP in the JNK3 binary
complex and cAPK ternary complex have been
superimposed; AMP-PNP is shown in purple.
The N-terminal domains of the two enzymes
are well aligned, but the difference in domain
orientation results in the misalignment of the
catalytic residues clustered in the C loop
(residues Arg188–Asn194 in JNK3) and DFG
loop (residues Asp207–Ala211 in JNK3),
such as Asp189 and Asp207, with those in
the N-terminal domain, such as Lys93.
amide of Gln75 and the sidechains of Gln75 and Lys93.
Comparison of different JNK isoform sequences shows that
the amino acids involved in ATP binding are conserved [3].
Two magnesium ions (M1 and M2) are observed in the
JNK3–MgAMP-PNP complex. The sidechain carbonyl
group of Asn194 contacts metal ion M1, which in turn
bridges the oxygens of the α- and γ-phosphoryl groups of
AMP-PNP. Asp207 interacts through water molecules with
M2, which is bound to the β- and γ-phosphoryl group
oxygens. In contrast, the corresponding residue in cAPK
(Asp184) coordinates both M1 and M2 directly. This sig-
nificant difference may play a role in the low activity of the
unphosphorylated conformation of the JNK3 enzyme. An
important role in metal chelation has been proposed for
Asp184 in cAPK, which requires direct interaction of the
aspartic residue with the metal ion [16,20]. Asp207 is
located within a loop called the ‘DFG loop’ which pre-
cedes the disordered β9 strand in unphosphorylated JNK3.
The structure of JNK3 suggests that upon phosphoryla-
tion, the refolding of the phosphorylation lip and domain
rotation should bring Asp207 closer to the nucleotide to
allow its direct interaction with the metal ion.
Structural comparison of JNK3 and cAPK reveals that the
two domains of JNK3 are rotated apart relative to their ori-
entation in the structure of cAPK (Figure 3). This twist
results in the misalignment of the two halves of the
catalytic site of JNK3. In the N-terminal domain of JNK3,
the putative catalytic residue Lys93 takes a position
similar to its corresponding residue in cAPK and forms
hydrogen bonds to the oxygen atoms of the α- and
β-phosphoryl groups of the nucleotide. The catalytic loop
(Arg188–Asn194) and the DFG loop (Asp207–Gly209) 
in the C-terminal domain are misaligned, however
(Figure 4b). The conserved Asp189 and Asp207 residues
are thought to be essential for protein kinase activity [21].
These residues are located 3 Å further away from Lys93 in
JNK3, compared to their corresponding residues in cAPK.
These differences suggest that the open conformation of
the domains in JNK3 may contribute to the low activity of
the unphosphorylated form of the enzyme.
The substrate specificity of JNK isoforms
The JNK3 binary complex is the first high-resolution
structure to be determined within the JNK subfamily. In
the region spanning residues Ser40–Ala418, JNK3 shares
92% and 87% amino acid identity with JNK1 and JNK2,
respectively. Thus, the JNK3 structure provides a frame-
work for understanding the substrate specificity of the dif-
ferent JNK isoforms. The nonconserved residues among
JNK isoforms are clustered mainly in two regions (see
Figure 1). One of these regions comprises the C-terminal
portion of αF and the following loop L13. Most of the
nonconserved residues in this region are solvent exposed
and located on the protein surface corresponding to the
peptide substrate binding channel identified in cAPK
(Figure 5). The position of these residues suggests that
they have a role in substrate-binding specificity. In
support of this hypothesis, the study of JNK chimeras has
shown that JNK specificity towards c-Jun is directed to
this region [22]. Furthermore, binding studies of JNK iso-
forms and various substrates have shown that JNK iso-
forms with higher homology in this region display similar
binding selectivity towards similar substrates [3]. The
other nonconserved region comprises α3L14 and the JNK
insertion, which lies on the protein surface adjacent to the
first nonconserved region (Figure 5). The location of this
region suggests that it might be an extended substrate-
binding site in JNK, and the sequence may be important
for substrate-binding specificity.
Biological implications
The c-Jun N-terminal kinases (JNKs) are members of
the mitogen-activated protein kinase family. JNKs are
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Figure 5
The substrate-binding specificity of JNK isoforms. The solvent-
accessible surface of JNK3 is shown with the modeled PKI inhibitor
(drawn as an orange tube) after the same superposition of the JNK3 and
cAPK structures as described in Figure 3. Surface areas corresponding
to the JNK3 residues not conserved in JNK1 and JNK2 are colored red.
Two clusters of divergent regions of JNK isoforms, identified from the
amino acid sequence alignment, are located next to each other on the
protein surface in the C-terminal lobe. This area, containing αF and L13,
has been shown to direct the substrate-binding specificity toward c-Jun
[3]. (The figure was generated using the program GRASP [41].)
serine/threonine kinases that are activated by dual phos-
phorylation of threonine and tyrosine residues. The phos-
phorylated residues (Thr221 and Tyr223) are located in a
Thr-Pro-Tyr segment within the activation loop which is
adjacent to the active site. A neuronal-specific isoform of
JNK, JNK3, has been linked to neuronal apoptosis
induced by kainic acid, indicating a role of JNK3 in the
pathogenesis of glutamate neurotoxicity [12].
We report here the X-ray crystal structure of the unphos-
phorylated form of JNK3 in complex with MgAMP-PNP.
The overall fold of JNK3 reveals similarities to the struc-
tures of cAMP-dependent protein kinase and two other
MAP kinases, ERK2 and p38. Unphosphorylated JNK3
assumes an open conformation, in which the N- and
C-terminal domains are oriented so that some of the
catalytic residues are misaligned. In addition, the phos-
phorylated region of the protein, termed the ‘phosphoryla-
tion lip’ partially blocks the peptide substrate binding site.
These structural features suggests that both global
(domain closure to bring the catalytic residues in close
proximity) and local (refolding of the lip to relieve steric
constraints to substrate binding) conformational changes
are required for JNK3 activation.
Crystallographic studies of ERK2, p38 and JNK3 have
shown that the region spanning β strand β9 and the
phosphorylation lip has the most diverse and labile con-
formation in unphosphorylated MAP kinases [13,14,23].
In the structure of phosphorylated ERK2, the conforma-
tion of this mobile region is stabilized by interactions
formed between the phosphates and residues near the
activation loop [19]. On the basis of the homology
between ERK2 and JNK3, we propose that the phos-
phorylation of Thr221 and Tyr223 may have similar
roles in activating JNK3 as they do in ERK2. In JNK3,
phosphorylation of Thr221 could promote domain
closure by interacting with Arg107 and Arg188,
whereas phosphorylation of Tyr223 might result in new
interactions with Arg227 and Arg230, which constitute
part of the substrate-binding pocket.
Elevated activity of JNKs has been implicated in a
variety of physiological processes ranging from T lym-
phocyte activation and apoptosis, to cardiac myocyte
hypertrophy [24–27]. Modulation of JNKs could there-
fore provide therapeutic intervention for disorders such
as autoimmune diseases, stroke, epilepsy and congestive
heart failure. The structure reported here provides a
framework for the design of selective JNK3 inhibitors.
Materials and methods
Expression and purification of JNK3
A search of the expression sequence tag (EST) database using the
program BLAST and the published JNK3α1 cDNA [3] as a query identi-
fied an EST clone (#632588) that contained the entire coding sequence
for human JNK3α1. Polymerase chain reactions (PCRs) using Pfu 
polymerase (Stratagene) were used to introduce restriction sites into the
cDNA for cloning into the pET-15B expression vector at the NcoI and
BamHI sites; the construct was expressed in Escherichia coli. Due to
the poor solubility of the expressed full-length protein (Met1–Gln422),
an N-terminally truncated protein starting at Ser40 (corresponding to
Ser2 of the JNK1 and JNK2 proteins [3]), preceded by methionine (initia-
tion) and glycine residues, was produced. The glycine residue was
added in order to introduce an NcoI site for cloning into the expression
vector. Further, systematic C-terminal truncations were performed by
PCR to identify a construct that gave rise to diffraction-quality crystals.
The construct was prepared by PCR using two deoxyoligonucleotide
primers — 5′ GCTCTAGAGCTCCATGGGCAGCAAAAGCAAAGTTG-
ACAA 3′ (forward primer with initiation codon italicized) and 5′ TAGCG-
GATCCTCATTCTGAATTCATTACTTCCTTGTA 3′ (reverse primer with
stop codon italicized) — and confirmed by DNA sequencing. The con-
struct, which encodes amino acid residues Ser40–Glu402 of JNK3α1
preceded by methionine and glycine residues, was used for the struc-
tural studies described in this paper. Control experiments indicated that
the truncated JNK3 protein has an equivalent kinase activity towards
myelin basic protein when activated with an upstream kinase MKK7 [15]
in vitro (TF and JTC, unpublished results).
E. coli strain BL21 (DE3) (Novagen) transformed with the JNK3 expression
construct was grown at 30°C in shaker flasks into log phase (OD600 ~ 0.8)
in Luria broth supplemented with 100 µg/ml carbenicillin. Isopropyl-β-D-
thiogalactopyranoside (IPTG) was then added to a final concentration of
0.8 mM and the cells were harvested 2 h later by centrifugation.
E. coli cell paste containing the truncated JNK3 protein was resuspended
in 10 volumes/g lysis buffer (50 mM HEPES, pH 7.2, 10% glycerol [v/v],
100 mM NaCl, 2 mM dithiothreitol [DTT], 0.1 mM phenylmethylsulfonyl
fluoride (PMSF), 2 µg/ml pepstatin, 1 µg/ml each of E-64 and leupeptin).
Cells were lysed on ice using a microfluidizer and centrifuged at
100,000 × g for 30 min at 4°C. The 100,000 × g supernatant was
diluted fivefold with buffer A (20 mM HEPES, pH 7.0, 10% glycerol [v/v],
2 mM DTT) and applied to an SP-Sepharose (Pharmacia) cation-
exchange column at 4°C. The column was washed with five column
volumes of buffer A, followed by five column volumes of buffer A contain-
ing 50 mM NaCl. Bound protein was eluted with a seven and a half
column volume linear gradient of 50–300 mM NaCl and the truncated
JNK3 protein was eluted between 150–200 mM NaCl. Eluted JNK3
protein from the SP–Sepharose column was dialyzed at ~ 1 mg/ml
against buffer B (25 mM HEPES, pH 7.0, 5% glycerol [v/v], 50 mM
NaCl, 10 mM DTT) overnight at 4°C and centrifuged at 3,000× g. The
supernatant was concentrated by ultrafiltration (Centriprep-30, Amicon)
to 10 mg/ml, centrifuged at 16,000 × g and stored at –70°C.
Kinase assays
A coupled spectrophotometric assay was used in which ADP generated
by activated JNK3 was converted back to ATP by pyruvate kinase (PK)
with the concomitant production of pyruvate from phosphoenol pyruvate
(PEP). Lactate dehydrogenase (LDH) reduces pyruvate to lactate with
the oxidation of NADH. NADH depletion was monitored at 340 nm using
a microplate reader for 20 min at 30°C. PK (100µg/ml), LDH (50 µg/ml),
PEP (2 mM) and NADH (200 µM) were added in large excess to the
reaction buffer containing 50 mM HEPES, pH 7.6 and 10 mM MgCl2.
JNK3 activity was measured in the presence of 200µM of an epidermal
growth factor receptor peptide substrate (KRELVEPLTPSGEAPN-
QALLR) and increasing concentration of ATP (2.5–800µM) [28]. Reac-
tions were initiated by the addition of 30 nM JNK3. Enzyme kinetic data
were analyzed by nonlinear regression in the program EZ-Fit (Perrella
Scientific, Amherst, NH). The specific kinase activities (kcat/Km) were
160,000 M–1s–1 and 190,000 M–1s–1 for the JNK3 lacking the N-terminal
39 residues (Ser40–Gln422) and the truncated JNK3 (Ser40–Glu402)
used for crystallographic studies, respectively.
Crystallization
Crystallization trials were performed by combining the hanging-drop
vapor diffusion technique and a sparse matrix search, in the presence
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and absence of MgAMP-PNP. No crystals were obtained in the
absence of MgAMP-PNP, although crystallization trials carried out in
the presence of MgAMP-PNP yielded an orthorhombic crystal form at
20°C over a reservoir solution containing 18–20% (v/v) polyethylene
glycol monomethyl ether (average Mr = 550), 10% (v/v) ethylene glycol,
20 mM β-mercaptoethanol and 100 mM HEPES (pH 7.5). The crystal-
lization droplet contained a mixture of 1 µl of reservoir solution plus 1 µl
of a protein solution that had been preincubated for 1 h with 1 mM
AMP–PNP and 2 mM MgCl2 on ice. The crystals belong to the
orthorhombic space group P212121 (a = 51.50 Å, b = 71.24 Å and
c = 107.60 Å) with one enzyme molecule per asymmetric unit. The
solvent content of the crystal is 44%. Before data collection, crystals
were equilibrated in their reservoir solution for 2–5 min before being
flash-frozen in nitrogen gas for X-ray data collection at –170°C.
Data collection and structure determination
X-ray data were measured on an Raxis IIC image plate, with mirror-
focused CuKα X-rays generated by a rotating-anode source. The dif-
fraction images were processed with the program DENZO and data
scaled using SCALPACK [29]. The data processing statistics are sum-
marized in Table 1.
The starting phases for JNK3 were obtained by molecular replacement
using coordinates of phosphorylated ERK2 (XX and KPW, unpublished
results) as search model in the program AMoRe [30]. The ERK2 atomic
model was modified by truncating to alanine for those residues that are
different from JNK3 and deleting those loops that have significant inser-
tions or deletions between ERK2 and JNK3. This hybrid model suc-
cessfully produced rotation and translation function solution for JNK3,
which provided a starting model with an R factor = 50% for reflections
between 10 and 4.0 Å resolution at the start of the refinement. Refine-
ment of the model using both conventional least-squares and simulated-
annealing procedures was done with X-PLOR software [31] using
8–2.3 Å data. The electron density corresponding to the AMP-PNP
molecule was visible from the map calculated using the initial model
phases, but AMP-PNP was not included in the model refinement until
the R factor dropped to 28% and the R free to 39%. The refined model,
at 2.3 Å resolution (Table 1), includes 339 residues of JNK3, one AMP-
PNP molecule, two Mg2+ and 183 water molecules. The electron-
density maps revealed several discrete regions of disorder, leading to
the omission of some amino acid residues from the final model. The N-
terminal residues 40–44 and C-terminal residues 401 and 402 are dis-
ordered. In addition, two central regions of the enzyme are disordered,
including residues 212–216 and 374–378. Finally, the sidechain atoms
for Tyr223 were not modeled beyond Cβ due to poor electron density.
The present R factor is 22.4% (R free = 27.4%). Anisotropic scaling
and bulk-solvent correction were applied at the final stage of the refine-
ment [32]. The peptide torsion angles for 337 out of 339 well-defined
residues fall within most favored or generally allowed regions of the
Ramachandran plot, as defined in the program PROCHECK [33].
Accession numbers
The coordinates of the JNK3 structure have been deposited in the
Protein Data Bank with accession code 1JNK.
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